$CELG..Celgene reports Phase II data in Crohn’s Disease to be presented at UEG
Celgene announced earlier that results from a double-blind, placebo-controlled, multicenter phase II trial of GED-0301 in 166 patients with active Crohn's disease will be presented at the United European Gastroenterology Week in Vienna, Austria. Scott Smith, President, Celgene Inflammation and Immunology, said, “Celgene is excited to pursue the clinical development program for this novel therapy in phase III trials in the near future.” The abstract was posted to the site for the event.
Sheff's Station...All Aboard...Sign Up Here!
